News

myMatrixx releases 2021 guidebook aimed at providing a quick reference resource on prior authorization medications and generic drug availability.

On February 27, 2021, Emergency Use Authorization (EUA) was granted to Janssen’s (Johnson & Johnson) COVID-19 vaccine (Ad26.COV2.S), by the U.S. Food and Drug Administration (FDA).

myMatrixx, an Express Scripts Company, is excited to have industry veteran Paul King join as Chief Client Officer.

myMatrixx Releases Position Paper on COVID-19 Vaccination and Workers' Compensation Coverage

Senior VP of Product Development, Hollie Lamboy discusses with R & I, the long-term staying power of COVID-19 and how it's impacting workers’ compensation.

myMatrixx is excited to launch our new Statehouse Watch, a comprehensive overview of the latest regulatory and legislative insights that look to shape the field

On Wednesday, January 27th, myMatrixx Chief Clinical Officer, Phil Walls, will join the Hartford’s Chief Medical Officer, Adam L. Seidner, in a virtual session for the National Workers’ Compensation and Disability Conference (NWCDC).

According to the Centers for Disease Control and Prevention, there have been about 21 million known COVID-19 infections in the U.S. since January 2020.

myMatrixx recently joined a coalition led by Evernorth to ensure that people vaccinated for COVID-19 have immediate access to their vaccination record.

“Long-haulers” are individuals who have been infected by COVID-19 and have recovered from the acute infection, but continue to have lingering symptoms. It’s important to monitor these patients as there’s emerging evidence of ongoing morbidity or chronic suffering from COVID-19.